Nipocalimab Becomes First Approved Treatment for Warm AIHA
The FDA approved nipocalimab (Imaavy) for warm autoimmune hemolytic anemia in adults and adolescents who have used corticosteroids. The drug blocks the neonatal Fc receptor to reduce pathogenic IgG autoantibodies while preserving B-cell function. In a phase II/III trial, 24% of treated patients achieved a durable hemoglobin response versus 8% with placebo.
Related stories
J&J's Imaavy becomes first approved therapy for rare anemia · Drug development
FDA Approves Second Drug for Ultra-Rare Bone Disease FOP · Drug development
Upadacitinib Shows Promising Hair Regrowth in Severe Alopecia Areata Trials · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “First Drug OK'd for Warm Autoimmune Hemolytic Anemia.” Browse more stories.